- Home
- XAIR vs ATHA Comparison
XAIR vs ATHA Comparison
Compare XAIR & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- ATHA
- Stock Information
- Founded
- XAIR 2011
- ATHA 2011
- Country
- XAIR United States
- ATHA United States
- Employees
- XAIR N/A
- ATHA N/A
- Industry
- XAIR Medical/Dental Instruments
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- XAIR Health Care
- ATHA Health Care
- Exchange
- XAIR Nasdaq
- ATHA Nasdaq
- Market Cap
- XAIR 17.0M
- ATHA 14.8M
- IPO Year
- XAIR N/A
- ATHA 2020
- Fundamental
- Price
- XAIR $2.43
- ATHA $0.36
- Analyst Decision
- XAIR Strong Buy
- ATHA Hold
- Analyst Count
- XAIR 1
- ATHA 3
- Target Price
- XAIR $11.00
- ATHA $0.50
- AVG Volume (30 Days)
- XAIR 8.8M
- ATHA 149.8K
- Earning Date
- XAIR 11-10-2025
- ATHA 11-06-2025
- Dividend Yield
- XAIR N/A
- ATHA N/A
- EPS Growth
- XAIR N/A
- ATHA N/A
- EPS
- XAIR N/A
- ATHA N/A
- Revenue
- XAIR $4,782,000.00
- ATHA N/A
- Revenue This Year
- XAIR $265.24
- ATHA N/A
- Revenue Next Year
- XAIR $136.17
- ATHA N/A
- P/E Ratio
- XAIR N/A
- ATHA N/A
- Revenue Growth
- XAIR 168.20
- ATHA N/A
- 52 Week Low
- XAIR $2.02
- ATHA $0.22
- 52 Week High
- XAIR $13.52
- ATHA $0.83
- Technical
- Relative Strength Index (RSI)
- XAIR 48.32
- ATHA 36.59
- Support Level
- XAIR $2.13
- ATHA $0.35
- Resistance Level
- XAIR $4.78
- ATHA $0.40
- Average True Range (ATR)
- XAIR 0.32
- ATHA 0.02
- MACD
- XAIR 0.05
- ATHA -0.00
- Stochastic Oscillator
- XAIR 11.82
- ATHA 11.86
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.